AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28076335 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 1733
Study 25869424 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ intervention (low exposure: mean = 149 ± 9 exercises/year)
Number of subjects: 23
Study 25869424 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ intervention (high exposure: mean = 314 ± 15 exercises/year)
Number of subjects: 23
Study 23471131 — intervention group
Group type: EXPERIMENTAL
Intervention: 900‐mg phosphate diet plus lanthanum carbonate (LC)
Number of subjects: 39
Study 23471131 — intervention group
Group type: COMPARATOR
Intervention: 900‐mg phosphate diet
Number of subjects: 39
Study 23471131 — intervention group
Group type: COMPARATOR
Intervention: lanthanum carbonate (LC) alone
Number of subjects: 39
Study 21455083 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic device (Phantom Desktop) simulating tactile elements of predefined clinical events.
Number of subjects: 24
Study 21455083 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic rendering of bone surface, skin pop, dura pop, and subcutaneous tissue.
Number of subjects: 24
Study 19144672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 100
Study 19144672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17404783 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-behavioral joint protection program (4 meetings over 8 months)
Number of subjects: 85
Study 15028362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) switched on
Number of subjects: 10
Study 15028362 — intervention group
Group type: COMPARATOR
Intervention: CRT switched off
Number of subjects: 10
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness (IMT) in common carotid artery (CCA)
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index (RI) in common carotid artery (CCA)
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index (RI) in internal carotid artery (ICA)
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART atherosclerosis risk score
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and IMT CCA
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and RI ICA
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and RI CCA
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve for IMT
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve for RI ICA
Number of subjects: 157
Study 11283379 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve for RI CCA
Number of subjects: 157
Study 9093988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 g CPP
Number of subjects: 22
Study 9093988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g CPP
Number of subjects: 22
Study 9093988 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g CPP
Number of subjects: 22
Study 9093988 — intervention group
Group type: COMPARATOR
Intervention: 0 g CPP (whole-grain cereal)
Number of subjects: 22
Study 9093988 — intervention group
Group type: COMPARATOR
Intervention: 1 g CPP (whole-grain cereal)
Number of subjects: 22
Study 9093988 — intervention group
Group type: COMPARATOR
Intervention: 2 g CPP (whole-grain cereal)
Number of subjects: 22
Study 7909874 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 7909874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost
Number of subjects: 0
Study 7909874 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2834938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (intravenous)
Number of subjects: 12
Study 2834938 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 29381802 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 22°C
Number of subjects: 16
Study 29381802 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 0°C
Number of subjects: 16
Study 29381802 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain tap water at room temperature (22°C)
Number of subjects: 16
Study 29381802 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain tap water at 0°C
Number of subjects: 16
Study 29381802 — intervention group
Group type: EXPERIMENTAL
Intervention: All stimuli (glucose at 0°C, glucose at 22°C, water at 0°C)
Number of subjects: 16
Study 29381802 — intervention group
Group type: COMPARATOR
Intervention: Plain water (all temperatures)
Number of subjects: 16
Study 27924501 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention including two lectures and printed resources (behavior cards, educational sheets)
Number of subjects: 1138
Study 27924501 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 1138
Study 27924501 — intervention group
Group type: COMPARATOR
Intervention: Control group following usual health education curriculum
Number of subjects: 1138
Study 26065720 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus conservative care (CC) for 3 months
Number of subjects: 33
Study 26065720 — intervention group
Group type: COMPARATOR
Intervention: Conservative care (CC)
Number of subjects: 33
Study 22900794 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer controlled 'Anaeject' device
Number of subjects: 100
Study 22900794 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 100
Study 21724782 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 150
Study 21724782 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 19195513 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + atorvastatin 20 mg
Number of subjects: 613
Study 19195513 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + atorvastatin 40 mg
Number of subjects: 613
Study 19195513 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 613
Study 19195513 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 613
Study 19195513 — intervention group
Group type: COMPARATOR
Intervention: ABT-335
Number of subjects: 613
Study 16867927 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 14
Study 16867927 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 14
Study 15309292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (lifestyle intervention)
Number of subjects: 506
Study 15309292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 506
Study 15309292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with FSIGT (n=83)
Number of subjects: 506
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 574
Study 11349176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and Penicillin G
Number of subjects: 574
Study 7537779 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface anesthesia
Number of subjects: 0
Study 7537779 — intervention group
Group type: COMPARATOR
Intervention: Conduction anesthesia
Number of subjects: 0
Study 7537779 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (control for nonspecific phenomena)
Number of subjects: 0
Study 2693136 — intervention group
Group type: EXPERIMENTAL
Intervention: Otrivine-Antistin eyedrops
Number of subjects: 16
Study 2693136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 326052 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (Diamox) administered to 24 eyes
Number of subjects: 49
Study 326052 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (control group)
Number of subjects: 49
Study 30855723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol immediate release (IR)
Number of subjects: 1447
Study 26932733 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 438
Study 26932733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 25738790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 80
Study 25738790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25403306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (1 tablet (125 mg) 3 times a day for 3 weeks) along with standard treatment
Number of subjects: 87
Study 25403306 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 87
Study 22404194 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care by a multidisciplinary team
Number of subjects: 0
Study 22404194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22404194 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 0
Study 20813517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 50 μg
Number of subjects: 90
Study 20813517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 100 μg
Number of subjects: 90
Study 20813517 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with saline placebo
Number of subjects: 90
Study 17667145 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 155
Study 17667145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 15833887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 125 microg twice daily for 3 weeks and once daily for a fourth week (dosage doubled for infants > or =1200 g)
Number of subjects: 32
Study 15833887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11981357 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 NRTIs + 1 protease inhibitor (stavudine + lamivudine + indinavir)
Number of subjects: 20
Study 11981357 — intervention group
Group type: COMPARATOR
Intervention: 2 NRTIs + 1 nonnucleoside reverse transcriptase inhibitor (stavudine + didanosine + nevirapine)
Number of subjects: 20
Study 9887850 — intervention group
Group type: EXPERIMENTAL
Intervention: PrimeTime program (very low‐fat vegetarian diet, smoking cessation, stress‐management training, moderate exercise, and group support)
Number of subjects: 100
Study 9887850 — intervention group
Group type: EXPERIMENTAL
Intervention: PrimeTime program
Number of subjects: 100
Study 9887850 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study 8918498 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based doses of CAF regimen (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 1435
Study 1832302 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1832302 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 6760379 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg trimipramine at bedtime for 4 weeks
Number of subjects: 61
Study 6760379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30672979 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 786
Study 30672979 — intervention group
Group type: EXPERIMENTAL
Intervention: High economic status
Number of subjects: 786
Study 28371461 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine + insulin glargine 300 U/mL (G + G300)
Number of subjects: 30
Study 28371461 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro + insulin glargine biosimilar (L + GB)
Number of subjects: 30
Study 26924183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 38
Study 26924183 — intervention group
Group type: COMPARATOR
Intervention: 3.0% hypertonic saline (HTS)
Number of subjects: 38
Study 23737158 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved stylet
Number of subjects: 40
Study 23737158 — intervention group
Group type: COMPARATOR
Intervention: Straight stylet
Number of subjects: 40
Study 21926570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge
Number of subjects: 1636
Study 21926570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge (3-day dressing change strategy)
Number of subjects: 1636
Study 21926570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge (7-day dressing change strategy)
Number of subjects: 1636
Study 21926570 — intervention group
Group type: COMPARATOR
Intervention: Major catheter-related infection
Number of subjects: 1636
Study 19232571 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-based skills training group
Number of subjects: 0
Study 19232571 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 17517349 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Management Program (HFMP) for 6 months
Number of subjects: 190
Study 17517349 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 190
Study 14699366 — intervention group
Group type: EXPERIMENTAL
Intervention: Median and ulnar nerve block
Number of subjects: 20
Study 14699366 — intervention group
Group type: COMPARATOR
Intervention: Cooling
Number of subjects: 20
Study 11472279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music in combination with therapeutic suggestions
Number of subjects: 90
Study 11472279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 90
Study 11472279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and music combined with therapeutic suggestions
Number of subjects: 90
Study 11472279 — intervention group
Group type: COMPARATOR
Intervention: Operation room sounds
Number of subjects: 90
Study 9720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 21
Study 9720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and alpha-interferon (proposed treatment)
Number of subjects: 21
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy or lesser resection
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: N0
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: N1
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: N2
Number of subjects: 100
Study 9008769 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life analysis
Number of subjects: 100
Study 2805034 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg daily
Number of subjects: 17
Study 2805034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 17
Study 961472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) administered as a single oral dose with food
Number of subjects: 9
Study 961472 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (INH) administered as a single oral dose in fasting state
Number of subjects: 9
Study 31477107 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred mobile application
Number of subjects: 0
Study 31477107 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 31477107 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker (both groups)
Number of subjects: 0
Study 28483500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (BL)
Number of subjects: 44
Study 28483500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 26018048 — intervention group
Group type: COMPARATOR
Intervention: MISSION‐Vet Implementation as Usual (IU) - standard training and access to the MISSION‐Vet treatment manuals
Number of subjects: 0
Study 26018048 — intervention group
Group type: EXPERIMENTAL
Intervention: MISSION‐Vet implementation augmented by GTO
Number of subjects: 0
Study 23397296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tramazoline with dexamethasone
Number of subjects: 21
Study 23397296 — intervention group
Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 21
Study 21744976 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal distrust priming
Number of subjects: 0
Study 21744976 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust priming (different method)
Number of subjects: 0
Study 21744976 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust priming
Number of subjects: 0
Study 18554601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group A)
Number of subjects: 86
Study 18554601 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (group B)
Number of subjects: 86
Study 16448302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination theory (SDT) intervention
Number of subjects: 1006
Study 16448302 — intervention group
Group type: COMPARATOR
Intervention: Community care (control)
Number of subjects: 1006
Study 12485379 — intervention group
Group type: EXPERIMENTAL
Intervention: full-coverage hard acrylic splint
Number of subjects: 52
Study 12485379 — intervention group
Group type: COMPARATOR
Intervention: palatal-only splint
Number of subjects: 52
Study 11185998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at 1 to 2 g/kg
Number of subjects: 0
Study 11185998 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional oral prednisolone (o‐PSL) (2 mg/kg for 2 weeks)
Number of subjects: 0
Study 11185998 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral methylprednisolone (mPSL) (5 mg/kg for 5 days)
Number of subjects: 0
Study 11185998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed parenteral methylprednisolone (PmPSL) (30 mg/kg for 3 days)
Number of subjects: 0
Study 11185998 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 9315400 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of attitudes and practice
Number of subjects: 0
Study 8349375 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil, 150 mg/day
Number of subjects: 30
Study 8349375 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine, 30 mg/day
Number of subjects: 30
Study 8349375 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 3304725 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (50 to 600 mg daily for 6 months)
Number of subjects: 25
Study 31923178 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated reminder letters (Arabic or Italian)
Number of subjects: 1227
Study 31923178 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder telephone calls in preferred language (Arabic or Italian)
Number of subjects: 1227
Study 31923178 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no translated letters)
Number of subjects: 1227
Study 31923178 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no telephone call)
Number of subjects: 1227
Study 30646223 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296
Study 30646223 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study 26675778 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/d
Number of subjects: 61
Study 26675778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24878174 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medications
Number of subjects: 692
Study 24878174 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 692
Study 22564825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually abused patients
Number of subjects: 125
Study 20175241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 mu g/kg iv administered over 5 min)
Number of subjects: 30
Study 20175241 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume to Dex group)
Number of subjects: 30
Study 17272962 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d quinapril plus 5 mg/d amlodipine besylate
Number of subjects: 374
Study 17272962 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/d quinapril
Number of subjects: 374
Study 17272962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 374
Study 17272962 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 374
Study 17272962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 374
Study 15340701 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-jet-cutting tonsillectomy
Number of subjects: 60
Study 15340701 — intervention group
Group type: COMPARATOR
Intervention: Conventional blunt dissection tonsillectomy
Number of subjects: 60
Study 12402374 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude allergen extracts from foods
Number of subjects: 292
Study 12402374 — intervention group
Group type: COMPARATOR
Intervention: Commercial allergen extracts
Number of subjects: 292